


 SENDERRA <i>Specialty Pharmacy</i> 3712 E. Plano Parkway, Ste. 200 Plano, TX 75074 <i>This prescription form is to be sent & received via fax</i>	Dermatology Oral/Topical Enrollment Form	Prescriber:	NPI:
	Physician Offices Call: 855-460-7928	Supervising Physician:	NPI:
	Fax: 888-777-5645	Address:	Tax ID:
		Phone:	Fax:
		Contact:	

PATIENT INFORMATION					
Name:	☐ M	☐ F	☐ Trans M	☐ Trans F	☐ Other
DOB: _____	SS#: _____				
Street:	City:	State:	ZIP:		
Phone:	Alt. Phone:	☐ English	☐ Spanish	☐ Other: _____	Wt.: _____ Ht.: _____

PRESCRIPTION			
Has the patient received a loading dose/starter kit? ☐ Yes Start Date: ____/____/____ ☐ No SHIP TO: ☐ Patient's Home ☐ Doctor's Office ☐ Other: _____			
Drug	Directions & Quantity	Refills	
Leqselvi™	8 mg Tablet	☐ Take 8 mg PO twice daily (Quantity: 60)	
Litfulo®	50 mg Capsule	☐ Take 50 mg PO once daily (Quantity: 28)	
Olumiant®	☐ 2 mg Tablet	☐ Take 2 mg PO once daily (Quantity: 30)	
	☐ 4 mg Tablet	☐ Take 4 mg PO once daily (Quantity: 30)	
Opzelura®	1.5 % Cream 60 gm	☐ Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)	
Otezla®	30 mg Starter Pack	☐ Take as directed per package instructions (Quantity: 55)	
	30 mg Tablet	☐ Take 30 mg PO twice daily (Quantity: 60)	
	XR Starter Pack	☐ Take as directed per package instructions (Quantity: 41)	
	XR 75 mg Tablet	☐ Take 75 mg PO once daily (Quantity: 30)	
Rhapsido®	25 mg Tablet	☐ Take 25 mg PO twice daily with or without food (Quantity: 60)	
Sotyktu™	6 mg Tablet	☐ Take 6 mg PO once daily (Quantity: 30)	
Vtama®	1% Cream 60 gm	☐ Apply a thin layer to affected area(s) once a day (Quantity: 1 tube)	

MEDICAL INFORMATION				
PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY				
PREVIOUS THERAPIES:	Tried & Failed (Duration):	Not Tolerated:	Contraindication:	 Affected Areas ☐ Face ☐ Feet ☐ Groin ☐ Hands ☐ Nails ☐ Scalp ☐ Other: _____ PASI Score: _____ BSA _____ % SALT Score: _____
☐ Methotrexate	☐ (_____)	☐	_____	
☐ Soriatane	☐ (_____)	☐	_____	
☐ Clobetasol	☐ (_____)	☐	_____	
☐ Stelara	☐ (_____)	☐	_____	
☐ Humira	☐ (_____)	☐	_____	
☐ Enbrel	☐ (_____)	☐	_____	
☐ _____	☐ (_____)	☐	_____	
PHOTOTHERAPY	Tried & Failed (Duration):	Not Tolerated:	Contraindication:	
☐ UVA /UVB	☐ (_____)	☐	_____	
☐ Patient cannot afford	☐ Photosensitivity	☐ Risk of Skin Cancer	☐ Distance from Office	
☐ L20.9 Atopic Dermatitis		☐ L40.0 Psoriasis Vulgaris (Plaque Psoriasis)		
☐ L50.8 Other Urticaria		☐ L63.9 Alopecia areata, unspecified		
☐ L80 Vitiligo		☐ Other: _____		
Active TB ruled out: ☐ Yes ☐ No Date: ____/____/____ Hep B ruled out/treated: ☐ Yes ☐ No Date: ____/____/____				

Additional Clinical Information:	
---	--

American Academy of Dermatology Consensus Statement on Psoriasis Therapies		
☐ Psoriasis is covering greater than 10% of body surface area ☐ Psoriasis is on palms, soles, head and neck, or genitalia ☐ Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints ☐ Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships		

PRESCRIBER SIGNATURE	
To Prescriber By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.	
Prescriber: _____	Date: ____/____/____

CONFIDENTIALITY NOTICE	
IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.	